Trial Information
Phase II Study Evaluating Docetaxel and CDDP as Neoadjuvant Chemotherapy Prior to Surgery, Followed by Adjuvant Docetaxel Plus CDDP in Chemonaive Patients With NSCLC Stage III
Inclusion Criteria:
- Histologically or cytologically confirmed NSCLC, respectable NSCLC stage IIIa T1-2 N2
or or unresectable stage IIIb 2.KPS>70%
3.Hb>10g/dl,ANC>2.0x109/L,Plt.>100x109/L4.T-bil.<1xULN,creatinine<1xULN,creatinine
clearance >60 ml/min,GPT/GOT<2.5xULN,ALP<5xULN
Exclusion Criteria:
- 1.Brain meta.2..Prior surgery,R/T, C/t or immunotherapy for NSCLC
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
overall response rate
Outcome Time Frame:
every cycle during 2nd-6th cycles
Safety Issue:
No
Principal Investigator
Chong-Jen Yu, M.D,Ph.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Internal Medicine, National Taiwan University hospital
Authority:
Taiwan: Department of Health
Study ID:
930911
NCT ID:
NCT00172380
Start Date:
February 2005
Completion Date:
March 2010
Related Keywords:
- NSCLC
- Carcinoma, Non-Small-Cell Lung